Takakura Kazuki, Koido Shigeo, Kan Shin, Yoshida Kosaku, Mori Masako, Hirano Yuta, Ito Zensho, Kobayashi Hiroko, Takami Shinichiro, Matsumoto Yoshihiro, Kajihara Mikio, Misawa Takeyuki, Okamoto Masato, Sugiyama Haruo, Homma Sadamu, Ohkusa Toshifumi, Tajiri Hisao
Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo, Japan Department of Oncology, The Jikei University School of Medicine, Tokyo, Japan
Anticancer Res. 2015 Jan;35(1):555-62.
BACKGROUND/AIM: Treatment combining dendritic cells (DCs) pulsed with three types of major histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1) peptides with chemotherapy may stabilize disease in pancreatic cancer patients.
Laboratory data from seven patients with pancreatic cancer who underwent combined DC/WT1-I/II vaccination and chemotherapy were analyzed. The DC phenotypes and plasma cytokine profiles were analyzed via flow cytometry.
The post-treatment neutrophil to lymphocyte (N/L) ratio was a treatment-related prognostic factor for better survival. Moreover, the mean fluorescence intensities (MFIs) of human leukocyte antigen (HLA)-DR and cluster of differentiation (CD)83 on DCs were significantly increased after chemoimmunotherapy. Interestingly, interleukin (IL)-6 level in plasma was significantly increased after chemoimmunotherapy in non-super-responders.
An increased N/L ratio, as well as HLA-DR and CD83 MFI levels may be prognostic markers of longer survival in patients with advanced pancreatic cancer who undergo chemoimmunotherapy.
背景/目的：用三种主要组织相容性复合体（MHC）I类和II类（DC/WT1-I/II）限制性肾母细胞瘤1（WT1）肽脉冲处理的树突状细胞（DC）与化疗联合治疗，可能会使胰腺癌患者的病情稳定。
分析了7例接受DC/WT1-I/II联合疫苗接种和化疗的胰腺癌患者的实验室数据。通过流式细胞术分析DC表型和血浆细胞因子谱。
治疗后中性粒细胞与淋巴细胞（N/L）比值是与治疗相关的、提示更好生存的预后因素。此外，化疗免疫治疗后DC上人类白细胞抗原（HLA）-DR和分化簇（CD）83的平均荧光强度（MFI）显著增加。有趣的是，非超反应者化疗免疫治疗后血浆白细胞介素（IL）-6水平显著升高。
N/L比值升高以及HLA-DR和CD83 MFI水平升高，可能是接受化疗免疫治疗的晚期胰腺癌患者生存时间更长的预后标志物。
